Carl Schmid and Dr. Milgram discusses the disparities in education and access to PrEP in the patient populations that need these medications the most.
Carl Schmid and Lynne H. Milgram, MD, MBA, CPE, share ideas that can provide more substantial access to PrEP and battle unmet needs in PrEP management.
It’s a real shame that not enough people are taking PrEP [preexposure prophylaxis] that should be. The CDC [Center for Diseases Control] indicates probably 1.2 million people are eligible to take PrEP, and only around 28% of those people eligible are currently taking it. There’s a number of reasons why. One, people don’t know about it. It’s still relatively new. In the communities that we need to reach—particularly black gay men, Latino gay men, black women—they’re not aware of it. It’s also a burden. You have to take a drug every day for a disease [when] you’re not sick. That’s changed. Some of the pills could be large, and that could be an issue. There are smaller pills right now, but you have to take the drug every day. It’s not just taking the pill. You have to be tested periodically for HIV. You have to make sure that you’re not living with HIV, and you have to go to the clinic or the doctor periodically for a certain test as well. It is a commitment, and there are a lot of hurdles. People may think that there’s a cost associated with it and too many steps and prior authorizations that people have to go through.
Carl Schmid describes the steps that can be taken to reduce inequities in PrEP uptake, focusing on community and provider education in episode 14 of Managed Healthcare Executive’s “Evaluating the Current and Future Opportunities for HIV PrEP.”
Details the policies and programs needed to overcome barriers to #PrEP access, including funding a national PrEP program with grants for community and provider outreach, coverage of associated services, and enforcing no-cost-sharing rules